A pilot study of campath-1H [alemtuzumab] induction therapy combined with Rituximab, Myfortic [mycophenolate sodium] and a short course of calcineurin inhibitor therapy to allow for a long term calcineurin inhibitor free regimen after renal transplantation.

Trial Profile

A pilot study of campath-1H [alemtuzumab] induction therapy combined with Rituximab, Myfortic [mycophenolate sodium] and a short course of calcineurin inhibitor therapy to allow for a long term calcineurin inhibitor free regimen after renal transplantation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2012

At a glance

  • Drugs Alemtuzumab (Primary) ; Ciclosporin (Primary) ; Mycophenolate sodium (Primary) ; Rituximab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2012 Planned end date changed from 1 Nov 2009 to 1 Apr 2007 as reported by ClinicalTrials.gov
    • 21 Aug 2009 Planned end date changed from 1 Nov 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 21 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top